Search

everythinglearnresearchcommunity

for

Search:↓

A breast cancer patient had lasting hair loss after chemotherapy, which improved with minoxidil treatment.

Patients and oncologists prioritize survival benefits, while payers focus on treatment costs.

Hair growth-promoting nutraceuticals do not block the cancer-fighting effects of tamoxifen and may enhance its action.

Certain nutraceuticals may enhance hair growth without affecting the cancer-fighting properties of tamoxifen.

Nutraceuticals that promote hair growth do not reduce tamoxifen's effectiveness in breast cancer treatment.

Some breast cancer patients on hormone therapy experience hair loss, and treatments like certain topical inhibitors and supplements may help without harming their cancer prognosis.

Hair loss from hormone therapy in breast cancer patients can be improved with minoxidil treatment.

Topical minoxidil improves hair loss in 80% of women with breast cancer undergoing endocrine therapy.

The guidelines advise against using testosterone and DHEA in women for most conditions due to safety and effectiveness concerns, but suggest considering testosterone for postmenopausal women with low sexual desire.

Chinese medicine may help hair growth and reduce hair loss in androgenetic alopecia.

Managing side effects of endocrine therapy is crucial to improve adherence and survival in breast cancer patients.

Safe treatments like minoxidil and spironolactone can help manage hair loss in breast cancer patients without increasing cancer risk.

Neoadjuvant endocrine therapy led to a better future outlook than chemotherapy, with no major quality of life differences.

Adjuvants, diet changes, and laser therapy may improve male pattern hair loss.

Oral dutasteride, minoxidil, and finasteride may help reduce hair loss in breast cancer survivors, but more research is needed.

Hidradenitis suppurativa may be related to hormones and patients often have metabolic disorders; more research is needed to understand this connection.

Non-hormonal treatments should be used first for sexual dysfunction in postmenopausal breast cancer patients on aromatase inhibitors, with hormones as a second option.

Drugs for hormone-related conditions might help treat mental disorders but could have serious side effects.

Carboxytherapy may help increase hair growth in alopecia patients but requires ongoing treatment.

Multimodal primary treatment improves survival in premenopausal breast cancer patients and is also beneficial for postmenopausal women.

High leptin levels may promote skin cancer and inflammation, suggesting potential for leptin-targeted therapies.

Botulinum toxin type A significantly reduces scalp psoriasis severity compared to placebo.

CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.

Oral minoxidil effectively improves hair regrowth in cancer survivors with late alopecia.

Hair regrowth treatments had modest benefits for patients with long-term hair loss after chemotherapy.

Low-dose oral minoxidil improved hair growth when topical treatments failed.

Certain drugs can worsen hair loss in people prone to androgenetic alopecia.

New treatments for PCOS focus on insulin resistance and reducing testosterone levels, along with traditional hormone therapies.

Formestane is a preferred second-line treatment for advanced breast cancer in postmenopausal women because it's effective and has fewer side effects.